Israel Gynecology Drugs Market By Therapeutics (Non-Hormonal Therapy vs. Hormonal Therapy), By Indication (Contraception, Gynecology Infections, Female Infertility, Postmenopausal disorders, Polycystic Ovary Syndrome, Osteoporosis, Gynecology Cancer, Endometriosis, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region, Competition, Forecast and Opportunities, 2028
Israel gynecology drugs market is expected to show an impressive growth during the forecast period, 2024-2028. The Israel gynecology drugs market is expected to boost due to factors such as increasing prevalence of gynecological disorders, growing aging population, rising awareness among women's health, technological advancements, and government initiatives. As women's healthcare continues to gain importance, the demand for gynecology drugs is expected to rise, leading to continued innovation and development in this field. The lifestyle of women in Israel has reportedly undergone a significant change leading to unhealthy lifestyle that increased the prevalence of gynecological disorders impacting the reproductive system. Gynecological therapies have been fueled in recent years by a sharp growth in the field of medical innovation for the treatment of diseases related to gynecology to meet unmet healthcare requirements.
Different brands operating in Israel and manufacturing same generic gynecological medications that are mostly prescribed have extremely significant price differences in the country. The cost of the medication is crucial for long-term adherence to the treatment and for effective drug therapy of any gynecological condition or disease. This can be accomplished by altering governmental policies and regulations, including focus on pharmacoeconomic and the benefits of opting to more affordable treatments so that women can easily avail medication.
Several pharmaceutical companies are active in the market for gynecology drugs for the development of novel gynecology treatments with advanced efficacy and low side effects. This element is promoting market growth. The major players in the Israel gynecology drugs market are becoming more interested in expanding their line of products. They are intensifying product launch activities to accomplish this goal. A few initiatives are supporting their delivery channels in the background. All these initiatives point to a hopeful rise in the market for Israel gynecology drugs.
Moreover, Israel has a robust pharmaceutical industry and is home to several leading companies that develop and manufacture gynecology drugs. Recent developments in gynecology drugs have led to improved treatment options for women's health issues. Non-hormonal treatments for menopausal symptoms, targeted therapies for gynecological cancers, injectable contraceptives, vaginal microbiome therapies, and personalized medicines are contributing to the growth of the Israel gynecology drugs market.
Increasing Prevalence of Gynecological Disorders
The incidence of gynecological disorders such as endometriosis, polycystic ovary syndrome (PCOS), and uterine fibroids is increasing in Israel. These disorders can cause severe pain, infertility, and other complications that significantly impact the quality of life of affected women. The rising incidence of these disorders is driving the demand for gynecology drugs in Israel, which can provide relief from symptoms and improve overall health outcomes. Moreover, PCOS is the most common occurring disorder which is one of the most common factors contributing to infertility among women and can only be treated by medication and healthy lifestyle. Changes in lifestyle, such as a sedentary lifestyle, poor diet, and stress, are also contributing to the increased risk of gynecological disorders. The availability of improved diagnostic methods, such as ultrasound and MRI, is also used regularly to detect gynecological disorders that may have gone undiagnosed in the past. Thus, with the emergence of more gynecological diseases, the demand for cost-effective drugs is also expected to rise in the country during the forecast period.
Growing Aging Population and Demand for Personalized Medicine
The aging population is another key driver of the Israel gynecology drugs market. As women age, they become more susceptible to gynecological disorders such as menopause, osteoporosis, and breast cancer. According to a report published by Permanent Mission of Israel, in 2018, 11.8% of Israel's population or 1,056,300 people were of 65 years and above, of whom 586,000 were women (55.5%). The aging population is also more likely to require gynecological surgery, which can further drive the demand for gynecology drugs for post-operative pain management and reduce the risk of complications in the country. Personalized medicines involve tailoring medical treatments to an individual's specific genetic makeup, lifestyle, and environmental factors, which is also in trend from the past few years. In gynecology, personalized medicines can be used to identify women who are at increased risk of gynecological cancers or who may be more likely to experience side effects from certain drugs. This can help healthcare providers choose the most effective treatment options for individual patients.
Rising Awareness of Women's Health
The growing awareness of women's health is another key driver of the gynecology drugs market. Women are increasingly taking charge of their health and seeking out treatments for gynecological disorders. This trend is driven by various factors, including increased education, access to information, and the rise of social media. Women are also more likely to discuss their health issues with their healthcare providers, leading to earlier diagnosis and treatment of gynecological disorders.
Moreover, the availability of over-the-counter drugs in the country is increasing awareness among women about their health and well-being. One notable Israel-based company is OCON Medical, which develops and manufactures IUDs (intrauterine devices) for contraception, as well as other medical devices for women's health. Their flagship product, the Ballerine IUB, a copper-based IUD that is designed to be more flexible and comfortable for women than traditional IUDs has been extensively adopted in Israel as well as globally as one of the most used gynecology drugs in the hormonal contraceptives category.
Another Israeli company that is active in the Israel gynecology drugs market is Teva Pharmaceuticals. Teva is one of the world's largest generic drug manufacturers and has a range of products for women's health, including hormonal contraceptives and treatments for menopausal symptoms.
In addition to these companies, there are also several Israeli startups that are developing innovative diagnostic systems for treatment and medication. For example, InnoLap Surgical is developing a minimally invasive surgical device for the treatment of uterine fibroids, while HeraMED is developing a connected pregnancy monitoring platform that can help detect potential complications in pregnancy and can be further treated by utilizing fetal medicines.
Many gynecology drugs are used in over half of all pregnancies, and prevalence of use is increasing with more awareness among the female population. The most used drugs include antiemetics, antacids, antihistamines, analgesics, antimicrobials, diuretics, hypnotics, tranquilizers, and others. There are many other medications, such as Clotrimazole, which are commonly used for treating infection and maintenance of women hygiene. Miconazole is another anti-fungal agent which is prescribed for various skin infections and for vaginal yeast infections. Thus, the Israel gynecology drugs market is expected to grow and innovate in the coming years, with Israeli companies and startups playing a significant role in advancing women's health in the country.
Targeted Therapies for Gynecological Cancers are Expected to Drive the Israel Gynecology Market
In the recent years, there has been a rise in the rate of gynecological cancers such as ovarian, cervical, and endometrial cancers which can be challenging to treat if not diagnosed at an early stage. However, in recent years, targeted therapies have been developed that can specifically target cancer cells, leaving healthy cells unharmed. For instance, Poly (ADP-ribose) polymerases (PARP) inhibitors have been approved for the treatment of ovarian and breast cancers that have specific genetic mutations. These drugs work by inhibiting the enzyme PARP, which is essential for repairing DNA damage in cancer cells.
According to a study in PubMed, women in Israel have significantly higher annual ASRs (age-standardized rates) for ovarian, cervical, and uterine malignancies. Cervical cancer strikes women at the later stage of life or after the onset of menopause. In the Israeli population, the distribution of cancer stages for uterine, ovarian, and cervical malignancies is comparable. Age-standardized incidence of ovarian cancer among Israeli women decreased significantly over the course of the study due to the availability of gynecological drugs in the market for early treatment of the symptoms. Pre-invasive cervical disease increased considerably at an age-standardized rate in older women. Advancements in technology have also led to the development of new and innovative gynecology drugs. The development of non-hormonal therapies for menopause symptoms has led to increased demand for these drugs. Similarly, the development of targeted therapies for gynecological cancers has led to improved survival rates and better health outcomes for affected women.
Market Segmentation
The Israel gynecology drugs market is segmented into therapeutics, indication, distribution channel, regional distribution, and company. Based on therapeutics, the Israel gynecology drugs market is fragmented into non-hormonal therapy and hormonal therapy. Based on indication, the market is segmented into contraception, gynecology infections, female infertility, postmenopausal disorders, polycystic ovary syndrome, osteoporosis, gynecology cancer, endometriosis, and others. By distribution channel, the Israel gynecology drugs market can be segmented into retail pharmacies, hospital pharmacies, and online pharmacies.
Market Players
Teva Pharmaceutical Industries Ltd., Pfizer Inc. GlaxoSmithKline plc, AstraZeneca Israel, Johnson & Johnson, Bayer Israel Ltd., Abbott Laboratories Ltd., Eli Lilly Israel Ltd., AbbVie Inc., and OCON Medical are some of the leading players operating in the Israel gynecology drugs market.
Report Scope:
In this report, the Israel gynecology drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Israel gynecology drugs market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Different brands operating in Israel and manufacturing same generic gynecological medications that are mostly prescribed have extremely significant price differences in the country. The cost of the medication is crucial for long-term adherence to the treatment and for effective drug therapy of any gynecological condition or disease. This can be accomplished by altering governmental policies and regulations, including focus on pharmacoeconomic and the benefits of opting to more affordable treatments so that women can easily avail medication.
Several pharmaceutical companies are active in the market for gynecology drugs for the development of novel gynecology treatments with advanced efficacy and low side effects. This element is promoting market growth. The major players in the Israel gynecology drugs market are becoming more interested in expanding their line of products. They are intensifying product launch activities to accomplish this goal. A few initiatives are supporting their delivery channels in the background. All these initiatives point to a hopeful rise in the market for Israel gynecology drugs.
Moreover, Israel has a robust pharmaceutical industry and is home to several leading companies that develop and manufacture gynecology drugs. Recent developments in gynecology drugs have led to improved treatment options for women's health issues. Non-hormonal treatments for menopausal symptoms, targeted therapies for gynecological cancers, injectable contraceptives, vaginal microbiome therapies, and personalized medicines are contributing to the growth of the Israel gynecology drugs market.
Increasing Prevalence of Gynecological Disorders
The incidence of gynecological disorders such as endometriosis, polycystic ovary syndrome (PCOS), and uterine fibroids is increasing in Israel. These disorders can cause severe pain, infertility, and other complications that significantly impact the quality of life of affected women. The rising incidence of these disorders is driving the demand for gynecology drugs in Israel, which can provide relief from symptoms and improve overall health outcomes. Moreover, PCOS is the most common occurring disorder which is one of the most common factors contributing to infertility among women and can only be treated by medication and healthy lifestyle. Changes in lifestyle, such as a sedentary lifestyle, poor diet, and stress, are also contributing to the increased risk of gynecological disorders. The availability of improved diagnostic methods, such as ultrasound and MRI, is also used regularly to detect gynecological disorders that may have gone undiagnosed in the past. Thus, with the emergence of more gynecological diseases, the demand for cost-effective drugs is also expected to rise in the country during the forecast period.
Growing Aging Population and Demand for Personalized Medicine
The aging population is another key driver of the Israel gynecology drugs market. As women age, they become more susceptible to gynecological disorders such as menopause, osteoporosis, and breast cancer. According to a report published by Permanent Mission of Israel, in 2018, 11.8% of Israel's population or 1,056,300 people were of 65 years and above, of whom 586,000 were women (55.5%). The aging population is also more likely to require gynecological surgery, which can further drive the demand for gynecology drugs for post-operative pain management and reduce the risk of complications in the country. Personalized medicines involve tailoring medical treatments to an individual's specific genetic makeup, lifestyle, and environmental factors, which is also in trend from the past few years. In gynecology, personalized medicines can be used to identify women who are at increased risk of gynecological cancers or who may be more likely to experience side effects from certain drugs. This can help healthcare providers choose the most effective treatment options for individual patients.
Rising Awareness of Women's Health
The growing awareness of women's health is another key driver of the gynecology drugs market. Women are increasingly taking charge of their health and seeking out treatments for gynecological disorders. This trend is driven by various factors, including increased education, access to information, and the rise of social media. Women are also more likely to discuss their health issues with their healthcare providers, leading to earlier diagnosis and treatment of gynecological disorders.
Moreover, the availability of over-the-counter drugs in the country is increasing awareness among women about their health and well-being. One notable Israel-based company is OCON Medical, which develops and manufactures IUDs (intrauterine devices) for contraception, as well as other medical devices for women's health. Their flagship product, the Ballerine IUB, a copper-based IUD that is designed to be more flexible and comfortable for women than traditional IUDs has been extensively adopted in Israel as well as globally as one of the most used gynecology drugs in the hormonal contraceptives category.
Another Israeli company that is active in the Israel gynecology drugs market is Teva Pharmaceuticals. Teva is one of the world's largest generic drug manufacturers and has a range of products for women's health, including hormonal contraceptives and treatments for menopausal symptoms.
In addition to these companies, there are also several Israeli startups that are developing innovative diagnostic systems for treatment and medication. For example, InnoLap Surgical is developing a minimally invasive surgical device for the treatment of uterine fibroids, while HeraMED is developing a connected pregnancy monitoring platform that can help detect potential complications in pregnancy and can be further treated by utilizing fetal medicines.
Many gynecology drugs are used in over half of all pregnancies, and prevalence of use is increasing with more awareness among the female population. The most used drugs include antiemetics, antacids, antihistamines, analgesics, antimicrobials, diuretics, hypnotics, tranquilizers, and others. There are many other medications, such as Clotrimazole, which are commonly used for treating infection and maintenance of women hygiene. Miconazole is another anti-fungal agent which is prescribed for various skin infections and for vaginal yeast infections. Thus, the Israel gynecology drugs market is expected to grow and innovate in the coming years, with Israeli companies and startups playing a significant role in advancing women's health in the country.
Targeted Therapies for Gynecological Cancers are Expected to Drive the Israel Gynecology Market
In the recent years, there has been a rise in the rate of gynecological cancers such as ovarian, cervical, and endometrial cancers which can be challenging to treat if not diagnosed at an early stage. However, in recent years, targeted therapies have been developed that can specifically target cancer cells, leaving healthy cells unharmed. For instance, Poly (ADP-ribose) polymerases (PARP) inhibitors have been approved for the treatment of ovarian and breast cancers that have specific genetic mutations. These drugs work by inhibiting the enzyme PARP, which is essential for repairing DNA damage in cancer cells.
According to a study in PubMed, women in Israel have significantly higher annual ASRs (age-standardized rates) for ovarian, cervical, and uterine malignancies. Cervical cancer strikes women at the later stage of life or after the onset of menopause. In the Israeli population, the distribution of cancer stages for uterine, ovarian, and cervical malignancies is comparable. Age-standardized incidence of ovarian cancer among Israeli women decreased significantly over the course of the study due to the availability of gynecological drugs in the market for early treatment of the symptoms. Pre-invasive cervical disease increased considerably at an age-standardized rate in older women. Advancements in technology have also led to the development of new and innovative gynecology drugs. The development of non-hormonal therapies for menopause symptoms has led to increased demand for these drugs. Similarly, the development of targeted therapies for gynecological cancers has led to improved survival rates and better health outcomes for affected women.
Market Segmentation
The Israel gynecology drugs market is segmented into therapeutics, indication, distribution channel, regional distribution, and company. Based on therapeutics, the Israel gynecology drugs market is fragmented into non-hormonal therapy and hormonal therapy. Based on indication, the market is segmented into contraception, gynecology infections, female infertility, postmenopausal disorders, polycystic ovary syndrome, osteoporosis, gynecology cancer, endometriosis, and others. By distribution channel, the Israel gynecology drugs market can be segmented into retail pharmacies, hospital pharmacies, and online pharmacies.
Market Players
Teva Pharmaceutical Industries Ltd., Pfizer Inc. GlaxoSmithKline plc, AstraZeneca Israel, Johnson & Johnson, Bayer Israel Ltd., Abbott Laboratories Ltd., Eli Lilly Israel Ltd., AbbVie Inc., and OCON Medical are some of the leading players operating in the Israel gynecology drugs market.
Report Scope:
In this report, the Israel gynecology drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Israel Gynecology Drugs Market, By Therapeutics:
- Non-Hormonal Therapy
- Hormonal Therapy
- Israel Gynecology Drugs, By Indication:
- Contraception
- Gynecology Infections
- Female Infertility
- Postmenopausal disorders
- Polycystic Ovary Syndrome
- Osteoporosis
- Gynecology Cancer
- Endometriosis
- Others
- Israel Gynecology Drugs Market, By Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Israel Gynecology Drugs Market, By Region:
- The Mediterranean coastal plain
- The Central Hills
- The Jordan Rift Valley
- The Negev Desert West
Company Profiles: Detailed analysis of the major companies present in the Israel gynecology drugs market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Types
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. VOICE OF CUSTOMER
5. ISRAEL GYNECOLOGY DRUGS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Therapeutics (Non-Hormonal Therapy vs Hormonal Therapy)
5.2.2. By Indication (Contraception, Gynecology infections, Female infertility, Postmenopausal Disorders, Polycystic Ovary Syndrome, Gynecology Cancer, Endometriosis)
5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2022)
5.3. Product Market Map
5.3.1. By Therapeutics
5.3.2. By Indication
5.3.3. By Distribution Channel
6. ISRAEL NON-HORMONAL THERAPY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value & Volume
6.2. Market Share & Forecast
6.2.1. By Indication
6.2.2. By Distribution Channel
7. ISRAEL HORMONAL THERAPY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Distribution Channel
8. MARKET DYNAMICS
8.1. Drivers
8.2. Challenges
9. MARKET TRENDS & DEVELOPMENTS
9.1. Recent Development
9.2. Mergers & Acquisitions
9.3. Product Launches
10. POLICY & REGULATORY LANDSCAPE
11. PORTERS FIVE FORCES ANALYSIS
11.1. Competition in the Industry
11.2. Potential of New Entrants
11.3. Power of Suppliers
11.4. Power of Customers
11.5. Threat of Substitute Products
12. ISRAEL ECONOMIC PROFILE
13. COMPETITIVE LANDSCAPE
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (As Reported)
13.5. Key Personnel
13.6. SWOT Analysis
13.6.1. Teva Pharmaceutical Industries Ltd.
13.6.2. Pfizer Inc.
13.6.3. GlaxoSmithKline plc
13.6.4. AstraZeneca Israel
13.6.5. Johnson & Johnson
13.6.6. Bayer Israel Ltd.
13.6.7. Abbott Laboratories Ltd.
13.6.8. Eli Lilly Israel Ltd.
13.6.9. AbbVie Inc.
13.6.10. OCON Medical
14. STRATEGIC RECOMMENDATIONS
15. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Types
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. VOICE OF CUSTOMER
5. ISRAEL GYNECOLOGY DRUGS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Therapeutics (Non-Hormonal Therapy vs Hormonal Therapy)
5.2.2. By Indication (Contraception, Gynecology infections, Female infertility, Postmenopausal Disorders, Polycystic Ovary Syndrome, Gynecology Cancer, Endometriosis)
5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2022)
5.3. Product Market Map
5.3.1. By Therapeutics
5.3.2. By Indication
5.3.3. By Distribution Channel
6. ISRAEL NON-HORMONAL THERAPY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value & Volume
6.2. Market Share & Forecast
6.2.1. By Indication
6.2.2. By Distribution Channel
7. ISRAEL HORMONAL THERAPY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Distribution Channel
8. MARKET DYNAMICS
8.1. Drivers
8.2. Challenges
9. MARKET TRENDS & DEVELOPMENTS
9.1. Recent Development
9.2. Mergers & Acquisitions
9.3. Product Launches
10. POLICY & REGULATORY LANDSCAPE
11. PORTERS FIVE FORCES ANALYSIS
11.1. Competition in the Industry
11.2. Potential of New Entrants
11.3. Power of Suppliers
11.4. Power of Customers
11.5. Threat of Substitute Products
12. ISRAEL ECONOMIC PROFILE
13. COMPETITIVE LANDSCAPE
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (As Reported)
13.5. Key Personnel
13.6. SWOT Analysis
13.6.1. Teva Pharmaceutical Industries Ltd.
13.6.2. Pfizer Inc.
13.6.3. GlaxoSmithKline plc
13.6.4. AstraZeneca Israel
13.6.5. Johnson & Johnson
13.6.6. Bayer Israel Ltd.
13.6.7. Abbott Laboratories Ltd.
13.6.8. Eli Lilly Israel Ltd.
13.6.9. AbbVie Inc.
13.6.10. OCON Medical
14. STRATEGIC RECOMMENDATIONS
15. ABOUT US & DISCLAIMER
